Tony Mok

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi request reprint A small step towards personalized medicine for non-small cell lung cancer
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    Discov Med 8:227-31. 2009
  2. pmc Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status
    She Juan An
    Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
    PLoS ONE 7:e40109. 2012
  3. doi request reprint Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    J Clin Oncol 31:1081-8. 2013
  4. doi request reprint Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation
    Tony S K Mok
    State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China
    Drugs 72:3-10. 2012
  5. doi request reprint Personalized medicine for non-small-cell lung cancer
    Tony S Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
    Expert Rev Anticancer Ther 10:1601-11. 2010
  6. doi request reprint Personalized medicine in lung cancer: what we need to know
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China
    Nat Rev Clin Oncol 8:661-8. 2011
  7. doi request reprint Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
  8. doi request reprint Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm
    Tony S K Mok
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 115:5143-54. 2009
  9. ncbi request reprint Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer
    Tony S K Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, China
    J Thorac Oncol 2:838-44. 2007
  10. ncbi request reprint Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study
    Tony S K Mok
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Oncology 71:292-6. 2006

Detail Information

Publications29

  1. ncbi request reprint A small step towards personalized medicine for non-small cell lung cancer
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    Discov Med 8:227-31. 2009
    ..It has become clear that personalized medicine for NSCLC is feasible. This small step towards personalized medicine represents a paradigm shift in the management of NSCLC...
  2. pmc Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status
    She Juan An
    Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
    PLoS ONE 7:e40109. 2012
    ..We aimed to define subgroups of patients with candidate driver genes in patients with non-small cell lung cancer...
  3. doi request reprint Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
    Tony Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
    J Clin Oncol 31:1081-8. 2013
    ....
  4. doi request reprint Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation
    Tony S K Mok
    State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China
    Drugs 72:3-10. 2012
    ..Earlier trials were limited by little information on the EGFR mutational status of the enrolled patients, and an ongoing phase III trial with translational biomarker analysis will provide more comprehensive data on the combination...
  5. doi request reprint Personalized medicine for non-small-cell lung cancer
    Tony S Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China
    Expert Rev Anticancer Ther 10:1601-11. 2010
    ..In this article, we summarize the current nonpersonalized therapies and examine the available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, or metastatic disease...
  6. doi request reprint Personalized medicine in lung cancer: what we need to know
    Tony S K Mok
    Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China
    Nat Rev Clin Oncol 8:661-8. 2011
    ..Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance...
  7. doi request reprint Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
    ..Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer...
  8. doi request reprint Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm
    Tony S K Mok
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, State Key Laboratory of Southern China, The Chinese University of Hong Kong, Hong Kong, China
    Cancer 115:5143-54. 2009
    ..This could potentially establish a new standard on the clinical utility of molecular targeted agents as maintenance therapy for patients with advanced-stage NSCLC...
  9. ncbi request reprint Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer
    Tony S K Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology and Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, China
    J Thorac Oncol 2:838-44. 2007
    ..This study was designed to evaluate the efficacy and tolerability of sequential administration of irinotecan and cisplatin and then docetaxel in patients with advanced non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study
    Tony S K Mok
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR, China
    Oncology 71:292-6. 2006
    ..In this study, the cytotoxic effects of patupilone (epothilone B; EPO906) were assessed in a panel of hepatocellular carcinoma (HCC) cell lines, and were compared with doxorubicin and the microtubule-stabilizing taxanes...
  11. ncbi request reprint A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
    T S K Mok
    Department of Clinical Oncology, Prince of Wales Hospital, Institute of Chinese Medicine, Hong Kong Cancer Institute, Chinese University of Hong Kong, Hong Kong Special Administrative Region HKSAR, China
    Ann Oncol 18:768-74. 2007
    ..This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy...
  12. doi request reprint Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial
    Tony S K Mok
    State Key Laboratory of Southern China, Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital Central, Hong Kong, China
    Asia Pac J Clin Oncol 7:4-12. 2011
    ..We report the results of a preplanned analysis of Asian patients enrolled in AVAiL...
  13. doi request reprint Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
    Yi long Wu
    Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
    Lancet Oncol 14:777-86. 2013
    ..We undertook FASTACT-2, a phase 3 study in a similar patient population...
  14. doi request reprint Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China
    Yi long Wu
    Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    Asia Pac J Clin Oncol 8:232-43. 2012
    ..Efficacy analyses were pre-planned in patients in China...
  15. ncbi request reprint Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China
    Yi long Wu
    Lung Cancer Research Institute and Cancer Center, Guangdong Provincial People s Hospital, Guangzhou, China
    J Thorac Oncol 2:430-9. 2007
    ..We investigated the relevance of demographic characteristics and EGFR mutations, correlations between the efficacy of gefitinib and EGFR mutations in NSCLC, and to identify individuals who would likely benefit from gefitinib...
  16. ncbi request reprint A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
    Brigette Ma
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, Hong Kong Cancer Institute, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Ngan Shing Street, Shatin, New Territories, Hong Kong
    Invest New Drugs 26:169-73. 2008
    ..We tested the hypothesis that 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) may enhance response to re-treatment with gemcitabine by enhancing intracellular uptake of gemcitabine in a phase II study...
  17. doi request reprint Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer
    Tony Mok
    Department of Oncology, Prince of Wales Hospital, Hong Kong, China
    J Thorac Oncol 5:1609-15. 2010
    ..We report safety and efficacy data from a subpopulation of East/South-East (E/SE) Asian patients enrolled in a global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment study)...
  18. ncbi request reprint Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    Lecia V Sequist
    Lecia V Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA James Chih Hsin Yang, National Taiwan University Hospital Chun Ming Tsai, Taipei Veterans General Hospital, Taipei Wu Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan Kenneth O Byrne, St James Hospital, Dublin, Ireland Vera Hirsh, McGill University, Montreal, Quebec, Canada Tony Mok, Prince of Wales Hospital, Hong Kong, China Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand Sergey Orlov, Pavlov State Medical University, St Petersburg Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Jaafar Bennouna, Institut de Cancérologie de l Ouest site René Gauducheau, Nantes, France Ki Hyeong Lee, Chungbuk National University Hospital
    J Clin Oncol 31:3327-34. 2013
    ..A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS)...
  19. ncbi request reprint Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group
    Wing M Ho
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong
    Med Oncol 22:303-12. 2005
    ..In a subgroup of patients with initial inoperable liver metastases, this regimen was able to down-stage the disease to an operable stage...
  20. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
    ..East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population...
  21. ncbi request reprint A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy
    Brigette Ma
    Department of Clinical Oncology and Sir Y K Pao Cancer Center, Prince of Wales Hospital, Shatin, Hong Kong
    Cancer Chemother Pharmacol 62:59-64. 2008
    ..The epidermal growth factor receptor (EGFR) is commonly overexpressed in nasopharyngeal carcinoma (NPC) and gefitinib inhibits NPC growth in vitro...
  22. doi request reprint Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization
    Simon Chun Ho Yu
    From the Department of Imaging and Interventional Radiology S C H Y, J W Y H, Vascular and Interventional Radiology Foundation Clinical Science Center S C H Y, J W Y H, Department of Clinical Oncology S L C, F M, B M, T M, W Y, and Department of Surgery P L, The Chinese University of Hong Kong, Room 2A061, 2 F, New Extension Block, Prince of Wales Hospital, 30 32 Ngan Shing St, Shatin, New Territories, Hong Kong SAR and Departments of Clinical Oncology E P H and Surgery K F L, J W, Prince of Wales Hospital, Shatin, Hong Kong SAR
    Radiology 270:607-20. 2014
    ....
  23. doi request reprint Management of hepatocellular carcinoma: beyond sorafenib
    Stephen L Chan
    State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
    Curr Oncol Rep 14:257-66. 2012
    ..This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed...
  24. ncbi request reprint Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer
    Calvin S H Ng
    Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shantin, NT, Hong Kong
    J Surg Oncol 79:101-6. 2002
    ..There have been few reports of its use in lung cancer. We investigate p16M in patients with non-small cell lung cancer (NSCLC)...
  25. ncbi request reprint Piloting electronic self report symptom assessment - Cancer (ESRA-C) in Hong Kong: a mixed method approach
    Carmen W H Chan
    The Nethersole School of Nursing, The Chinese University of Hong Kong, China
    Eur J Oncol Nurs 15:325-34. 2011
    ..This study aimed to assess the feasibility and acceptability of using an electronic self report symptom assessment tool among Chinese oncology patients...
  26. ncbi request reprint A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)
    Tony Mok
    State Key Laboratory of Southern China, Hong Kong Cancer Institute, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China Russian Research Oncology Center n a N N Blokhin of the Russian Academy of Medical Sciences, Moscow, Russia Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary Department of Pulmonology, Markusovszky University Hospital, Budapest, Hungary Arkhangelsk Regional Clinical Oncology Dispensary, Perm, Russia Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan Roche Products Limited, Welwyn Garden City, Hertfordshire, United Kingdom F Hoffmann La Roche Ltd, Basel, Switzerland and Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research DZL, Grosshansdorf, Germany
    J Thorac Oncol 9:848-55. 2014
    ....
  27. ncbi request reprint Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer
    Tony Mok
    The Chinese University of Hong Kong, Sir YK Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China
    Future Oncol 10:813-22. 2014
    ..Further clinical trials are underway to evaluate the efficacy of dacomitinib in non-small-cell lung cancer. ..
  28. doi request reprint Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
    Masahiro Fukuoka
    Kinki University School of Medicine, Osaka, Japan
    J Clin Oncol 29:2866-74. 2011
    ..This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status...
  29. doi request reprint Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers
    Vincent Wai Sun Wong
    Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong State Key Laboratory in Oncology in South China
    J Clin Oncol 28:1660-5. 2010
    ..Hepatitis B virus (HBV) infection is an important etiology for hepatocellular carcinoma (HCC). We aim to develop a simple clinical score in predicting the risk of HCC among HBV carriers...